Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Truth hurts... can't spin the 10-Q
Maybe the DOJ showed up with the warrants...
I'm still confused by all the cryassing from long term holders.
Unless they are part of the cabal too?!?
IMO, $AVXL's stock price will go however the indexes go without an outside force like Rett results.
Looks like Dr. Missling didn't want to mix science with investing presentations as is usual, but I know many eyes are watching and that's a good time to release the data.
If "investors" learned the basics of how to read a 10-K versus reading echo chamber hype they would be much wealthier.
I haven't been following $CYDY for very long, and have never had a position long or short, but I do like to watch a good stock story unfold.
Unfortunately this is a sad story.
Shorts smell blood. As regarding $CYDY, the chart, financials, and lack of robust trial data is in shorts favor.
The real question the SEC and DOJ should be asking, is WHO IS PAYING ADAM FEUERSTEIN?
I agree many lies out there. That's why my DD and posts are primary sourced from SEC documents.
No duh... I never said they were if your comment was to me.
Simply commenting on how tomorrow could roll and be regulation FD compliant.
A early press release and 8-K of Rett data, followed by a "virtual live" JPM presentation highlighting the new information is compliant.
Minor correction, $CYDY filed a S-3 secondary shelf offering on March 3, 2021 that has not been declared effective and probably never will be.
Link to S-3: https://www.sec.gov/Archives/edgar/data/0001175680/000119312521067849/d435677ds3.htm
"Release PR, do the JPM then do the HC or vice versa." Is fully compliant with regulation FD and would make for an exciting day.
No new information was provided at the HC Wainwright conference, but not following through with their own timeline is frustrating even if nothing new was presented.
A webcast of the on-demand presentation will be available beginning Monday, January 10, 2022 on the Company's website at www.anavex.com.
Incorrect in the $CYDY situation, as the flow of equity is restrained without an effective shelf S-3. Therefore $CYDY is restricted to regulation D deals and the burdens of rule 144 that come with it.
There’s no way we’ll go bankrupt it’s just a matter of how much dilution there will be.
"REALITY IS SAD", true, but it's all good and caveat emptor when using proper disclosure and forward looking language.
How did you derive $0.50?
I've been using the warrant exercise prices as the support levels the MM's would try to hold for their share selling buddies.
I expected a death spiral if $1 fell, but nothing that pegged $0.50 specifically.
Great guess of a round psychological number if a guess.
The financials show $CYDY is in a dire situation and common equity is worthless.
The $2.50 per share cash requirement wasn't even a true "cost to carry" in this low interest rate environment.
Bravo...Bravo!
This happens so often in OTC.
I'm absolutely positive retail warrant holders have had a very difficult time exercising and selling $CYDY under rule 144.
Most brokerage firms probably won't even accept in the certificates or a transfer in. Plus many brokers now charge commission for OTC trades starting 2022.
Retail investing tip..avoid OTC and especially with warrants.
I thought the last financials were bad. The common equity is worthless.
Inside joke in the phrase "HOLD LONG!!!" for Anavex investors.
At least that's how I took it.
HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
HOLD LONG, DON'T LET SHORTY STEAL YOUR SHARES... LOL!!!!
Good luck financing this disaster as $CYDY can only do regulation D offerings of unregistered shares.
Ain't nobody got time for 6 months of rule 144 risk on that crap!
But with 12% placement bonus, at $0.40 plus generous warrants, maybe a firm will do the deal.
"there has never been any validated good news," or productive news either.
"The last proactive video, NP said he would go Fund Raise."
I'm sure he will try as there are firms lower thanFife and Paulson that will do small toxic deals. However, I bet warrants won't be an option anymore. The toxic terms of equity financing will be at a direct discount to the market price.
Executive compensation versus actual progress is what first clued me in $CYCY was all hype no substance.
A friend asked me to look at $CYDY in March 2021 $CYDY was $2.79 when I gave the liquidate it all advice...
Now if leronlimab has potential as a compound, the jury is still out, but one thing I'm sure of is as long as $CYDY owns it's worthless inside this negative equity stock promotion.
So if it works.... Free leronlimab!!!
"The average warrant conversion is $0.86 so they can't even get the cash from the warrant conversion like they have done regularly with special incentives. Swirling down the drain."
That sounds about right for the warrants. Did you notice the preferred B shares are being converted and sold too?
Series B convertible preferred stock, $0.001 par value; 400 shares authorized, 19 and 79 shares issued and outstanding at November 30, 2021 and May 31, 2021, respectively
This is where it gets ugly when they all race for the exit.
Last one out is a rotten egg!
I think there is a regulation FD issue for lack of disclosure of the Samsung issue...
Also, I find it interesting no 8k was filled when CYDY went into default for Samsung considering how much capital they have given them and how much they talk about them. Material event to me if I ever knew one.
If only LL was approved the world would be saved...LOL!
No worries $0.50 appears to be the average toxic exercise price floor... sell away.
Some warrant holders re-negotiated for $1 warrants... suckers!!!! Bet they are pissed off at their council when other counterparties received much better deals.
Average retail shouldn't even be messing around with PIPE runner tricks with warrants, but here we are.
$0.50 will be the next support based on the lowest average prefered and warrant exercise prices.
Below $0.50 almost all "investors" will be underwater with little inducement to convert, hold 6 months, then sell common equity shares.
It's the prefered shares conversions that will hammer the market more than warrants.
Hydro or other accountant types feel free to double check the toxic exercise price averages.
Noticed some preferred "B" shares were converted to common shares.
The $1 down to $0.30 warrant conversions AND the preferred "B" holders are converting and selling common shares.
This is exactly as I've been warning people was happening.
Many different entities have shares to sell and $CYDY is obligated to play the pump so they can dump. Otherwise Fife and company won't give them any more money regardless of the free 12% and additional incentives.
"Apparently SOMEBODY thinks theyre gonna be moving some Leronlimab."
LOL, not really, but somebody was able to sell their $0.30 warrant exercise stock on the "news".
Some sucker's paid $0.819 on today's PR.
LOL, $CYDY is such a classic OTC piece of garbage.
Free Leronlimab from $CYDY!!!!
$CYDY does bad deal after bad deal to the detriment of common equity.
Not a chance this rebounds to $1 ...
... it will rebound to $1.00 first before it inevitably declines.
Nope, new 52 week low is coming.
"... at the H.C. Wainwright BioConnect Conference. The conference is being held on January 10-13, 2022 virtually."
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220110:nGNX2W4bnD&default-theme=true
Institutional holdings of $AVXL has be steadily increasing and the stock price now correlates much more with the indexes that in the early days.
https://fintel.io/so/us/avxl
This site, in site of ads and paywalled data, is a much better source of data than the very delayed data available elsewhere.
In the visual range I see potential as a rare disease platform company with blarcamesine in Rett, Fragile X, Angelmans, and "undisclosed".
Then after the MJFF human PD imaging data trial is complete the larger indications such as Alzheimer's, Parkinson's Disease and other dementias.
(Time to ditch the rat skulls in the slides.. LOL)
https://www.anavex.com/therapeutic-candidates
Cool stuff ahead.
In the "Beyond Visual Range" category there are the first stages for 3-71, the next novel therapy that modulates S1R and the muscarinic receptors.
https://www.anavex.com/post/independent-research-describes-anavex-3-71-as-potent-cognitive-enhancer-in-alzheimer-s-disease-model
https://www.anavex.com/press-releases/anavex-presents-new-data-on-preclinical-development-of-anavex-3-71
https://www.anavex.com/press-releases/u.s.-fda-grants-orphan-drug-designation-to-anavex-3-71-for-the-treatment-of-frontotemporal-dementia
The possibility for maximum gain is often at another's maximum pain.
Damn that chart looks UGLY!!!!